Lexicon Pharmaceuticals (LXRX) said Friday it plans to cut 60% of its workforce, with most departures effective by Dec. 31, as part of a shift to focus on its clinical development pipeline.
The company said it will eliminate commercial operations, including promotional efforts for Inpefa and planned activities for Zynquista, to conserve cash and advance high-impact research programs.
The restructuring follows an FDA letter identifying deficiencies in the new drug application for Zynquista as an adjunct to insulin therapy for type 1 diabetes and chronic kidney disease.
The drug developer said that Inpefa will remain available to patients and prescribers.
Lexicon anticipates a $100 million reduction in 2025 operating costs, in addition to $40 million in savings announced earlier this year.
The company will focus on key programs, including a phase 2 study of LX9211 for diabetic peripheral neuropathic pain, a phase 3 study of sotagliflozin for hypertrophic cardiomyopathy, and IND-enabling studies of LX9851 for obesity and cardiometabolic disorders.
Lexicon shares were 4% lower in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。